Folgen
-
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
-
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
-
Fehlende Folgen?
-
Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.
-
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.
-
Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.
-
Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.
-
Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.
-
Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.
-
David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.
-
Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.
-
Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.
- Mehr anzeigen
